Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group.

Autor: Franco Pérez F; Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. Electronic address: f3franc@gmail.com., Lavernia J; Department of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain., Aguiar-Bujanda D; Department of Medical Oncology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Spain., Miramón J; Department of Medical Oncology, Hospital Serranía de Ronda, Málaga, Spain., Gumá J; Department of Medical Oncology, Hospital Universitari Sant Joan de Reus, Reus, Spain., Álvarez R; Department of Medical Oncology, Hospital Universitario Virgen de la Salud, Toledo, Spain., Gómez-Codina J; Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain., Arroyo FG; Department of Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra, Spain., Llanos M; Department of Medical Oncology, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain., Marin M; Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Alfaro J; Department of Medical Oncology, Instituto Oncológico de Kutxa, Donistia, Spain., Quero C; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Delgado M; Department of Medical Oncology, Hospital Universitario San Cecilio, Granada, Spain., Nogales E; Department of Medical Oncology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain., Menarguez F; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain., Martinez N; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain., Torrente M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain., Royuela A; Department of Biostatistics, Hospital Universitario Puerta de Hierro, Majadahonda, Spain., Abreu D; Department of Medical Oncology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canarias, Spain., Provencio M; Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2017 Mar; Vol. 17 (3), pp. 186-191. Date of Electronic Publication: 2016 Sep 17.
DOI: 10.1016/j.clml.2016.09.004
Abstrakt: Introduction: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary glands unilaterally or bilaterally, and can also affect the regional lymph nodes.
Materials and Methods: We reviewed 55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were calculated.
Results: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%), chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%, respectively.
Conclusion: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good control of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the scarce incidence of these lymphomas.
(Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: